• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)

Renal Disease Treatments: Products and Therapies

  • Publication Date:November 2009
  • Publisher:BCC Research
  • Product Type: Report
  • Pages:187

Renal Disease Treatments: Products and Therapies

This Report

Forecasts for the U.S. market in products and services, providing data for 2008 and estimates for 2009, and projections for the market and compound annual growth rates (CAGRs) from 2009 to 2014 Focus on pharmaceutical products, dialysis therapies, and surgical procedures in the U.S. market for renal failure treatment Breakdown of the dialysis equipment market by type and manufacturer, and the dialysis services market by provider Detailed company profiles

Study Goal and Objectives

This BCC Research market opportunity study provides an in-depth analysis of the market for kidney failure treatment products and services, forecasting growth and trends in the various sectors over the next 5 years. Products and services will include those for treating acute renal failure, chronic renal failure, and end-stage renal disease, the final phase of chronic kidney failure. Market sectors to be covered in this report include pharmaceuticals used to address the conditions associated with kidney failure (i.e., hypertension, diabetes, and anemia); hemodialysis and peritoneal dialysis products and services; and surgical procedures used to keep the end-stage kidney patient alive (i.e., surgeries to create vascular access sites for dialysis, and kidney transplantation). The conclusions are illustrated with important statistical and analytical information on markets, industry structure and dynamics, as well as technological developments.

Reasons For Doing The Study

Kidney failure is the ninth-leading cause of death in the U.S., accounting for about 85,000 fatalities each year. Approximately 27 million Americans currently have chronic kidney disease, while another 20 million are at increased risk for developing chronic kidney disease. More than 500,000 individuals currently are being treated for kidney failure via dialysis or kidney transplant. Nearly 400,000 individuals receive dialysis treatments three or more times each week. Over the last decade, the chronic kidney disease rate has risen more than 25%. During the past 5 years, the number of new patients with kidney failure has averaged 90,000 to more than 100,000 annually.

In addition to the individuals struggling with chronic kidney disease, more than 200,000 people suffer acute renal failure in the U.S. each year. The rate of ARF diagnosis as a percentage of all kidney failure hospitalizations rose from 7.3% in 1980 to 60% in 2005. Experts note that some of the increase may be due to changes in the definition of acute renal failure. Many of these patients acquire the condition while already hospitalized for other problems. While sometimes temporary and reversible, acute renal failure also may lead to chronic kidney failure. The total annual cost of treating end-stage renal disease caused by either chronic kidney disease or acute renal failure is in the tens of billions of dollars each year. Much of the care for chronic kidney disease and end-stage renal disease is provided in the outpatient setting; however, the number of hospitalizations for acute renal failure and chronic kidney failure is substantial.

Over the past 20 years, both the numbers and rates of kidney disease hospital discharges have increased, especially among adults age 65 years or older. In addition, a shift has occurred for reported hospitalizations in the type of kidney disease, from chronic to acute renal failure. An increasing number of kidney disease hospitalizations also are associated with a concomitant diagnosis of diabetes mellitus or hypertension. For both acute and chronic conditions, and outpatient or in-hospital settings, nearly all of these kidney problems require some sort of intervention, whether pharmaceutical, mechanical, and/or surgical. This report details the various products and services used to address renal failure. Three categories of treatment are most prevalent: prescription medications, dialysis (hemodialysis, peritoneal dialysis, and continuous renal replacement therapy), and surgical intervention, which are often used in combination to treat a single case of renal failure.

Intended Audience

This study aims to provide those interested in investment, acquisition, or expansion into the renal failure treatment market with specific, detailed information crucial to making informed decisions. Senior marketing personnel, venture capitalists, executive planners, and research directors should find the report of value. Readers who simply wish to understand how regulations, market pressures, and technology interact in the renal failure treatment industry also will find the study worthwhile.

Scope of Report

Five-year projections for market activity and value are provided. Treatment types and trends for acute and chronic renal failure, pricing considerations for medications, dialysis products (dialysis machines, dialysates and dialyzers) and therapies, and surgical procedures; companies, industry structure and participating companies are included in the study. Not included in the study are market analyses for water treatment systems used in making dialysate solutions, or lower-cost dialysis supplies such as fistula needles, bloodlines, topical anesthetics, wipes, bandages, dressings, etc. Diagnostics, testing, and other lab services are not included, nor are training sessions for home hemodialysis or peritoneal dialysis. For hospitalizations related to acute renal failure and vascular access maintenance, therapy/surgical costs reflect, as much as possible, only those expenses directly related to kidney care. Charges for the stay in intensive care, ventilation, laboratory services, and drugs not directly related to renal failure treatment are not included. Ambulance costs, nursing home expenses, and non-nephrology-related physician fees also are excluded.

Information Sources

Research for this report began with an in-depth analysis of technical and business literature, as well as a review of the history of the technology. Information from industry experts, company representatives, government researchers, and university scientists provided the basis for an assessment of the industry. Specific information sources include company annual reports, the Centers for Disease Control and Prevention, U.S. Renal System Database, National Kidney Foundation, Organ Procurement and Transplantation Network, Network 13, National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, National Kidney Disease Education Program, product literature from pharmaceutical and equipment manufacturers, scientific journals, and patent searches.

The study is divided into key chapters dealing with the three types of interventions used in treating kidney failure: medication, dialysis, and surgery. The report makes projections for each market in terms of constant 2009 dollars. Historical values are presented for the given year, with focus on the U.S. market. Overseas activity is mentioned briefly in order to put the U.S. market into a global context.

Analyst Credentials

During the past 13 years, Susan Hanft has authored more than 14 BCC market opportunity reports in the fields of membrane technology, medical devices, water and wastewater treatment, and bioenergy.

  • Chapter- 1: Introduction -- Complimentary
    • Study Goal and Objectives
    • Reasons for Doing The Study
    • Intended Audience
    • Scope of Report
    • Information Sources
    • Analyst Credentials
    • Related BCC Reports
    • BCC Online Services
    • Disclaimer
  • Chapter-2: Summary
    • Summary
    • Summary Table The U.S. Market for Renal Failure Treatment, through 2014 ($ Millions)
    • Summary Figure U.S. Market for Renal Failure Treatment, 1996 - 2014 ($ Millions)
  • Chapter-3: Overview
    • Kidney Function
    • Kidney Disease
    • Table 1 Diseases Leading to Renal Failure
    • Detecting Kidney Disease
    • Typical Tests
    • Patient Populations
    • Table 2 Estimated Arf, Ckd, and Esrd Populations, Including Transplant Recipients and Routine Dialysis Patients, 1996-2009
    • Figure 1 Estimated Arf, Ckd, and Esrd Populations, Including Transplant Recipients and Routine Dialysis Patients, 1996-2009
    • Hospitalizations with Renal Failure Listed as A Diagnosis
    • Figure 2 Age-Specific Hospitalization Rates* for Kidney Disease,† by Age Group -- National Hospital Discharge Survey, United States, 1980-2005
    • Figure 3 Age-Adjusted Hospitalization Rates for Kidney Disease by Type, 1980-2005
    • Table 3 Number of Hospitalizations and Age-Adjusted Hospitalization Rates for Kidney Disease, by Sex and Year, National Hospital Discharge Survey, 1980 - 2005
    • Figure 4 Number of Hospitalizations for Kidney Disease, by Sex and Year, National Hospital Discharge Survey, 1980 - 2005
    • Who Pays The Costs of Kidney Disease?
    • What Medicare Covers
    • Medicare' S Esrd Program
    • Breakdown of Esrd Population by Payer
  • Chapter-4: Acute Kidney Failure
    • Incidence of Chronic Kidney Failure
    • Causes of Chronic Kidney Failure
    • Table 6 Primary Causes of Kidney Failure (% of Patients)
    • Figure 7 Primary Causes of Kidney Failure (% of Patients)
    • Figure 8 Ckd Predictors in The U.S. Population Aged 20 and Older
    • Ckd Stages
    • Table 7 Stages of Chronic Kidney Disease
    • Stage 1
    • Stage 2
    • Stage 3
    • Stage 4
    • Stage 5 (Esrd)
    • Number of Individuals with Ckd
    • Table 8 Patients with Ckd and Awareness of The Disease, by Stage, 2009 (Number and %)
    • Figure 9 Patients with Ckd and Awareness of The Disease, by Stage 2009 (%)
    • Characteristics of The Ckd Patient Population
    • Table 9 Ckd Patient Characteristics (Column %)
    • Treatment Goals
    • Esrd
    • Table 10 Esrd Treatment, by Modality (Percentage and Number of Patients)
    • Figure 10 Esrd Treatment, by Modality (Percentage of Patients)
    • Table 11 Dialysis for Esrd, by Treatment Modality, 2009
    • Figure 11 Dialysis for Esrd, by Treatment Modality, 2009 (%)
    • Costs of Chronic Kidney Disease
    • Table 12 Inpatient/Outpatient and Physician /Supplier Net Costs for Ckd ($, per Patient per Month, 2006)
    • Table 12 (Continued)
    • Figure 12 Pppm Expenditures for Ckd Patients, 1993 - 2006 (Medicare, Medicare/Medicaid, Medstat [Employer Paid Insurance])
    • The U.S. Market for Treating Chronic Kidney Failure and End-Stage Renal Disease
    • Table 13 The U.S. Market for Ckd/Esrd Treatment by Type, 1996 - 2014 ($ Million)
    • Figure 13 The U.S. Market for Chronic Renal Failure Treatment by Type, 1996-2014 ($ Million) 46
  • Chapter-5: Chronic Kidney Failure
  • Chapter-6: Pharmaceuticals Used in Renal Failure Treatment
    • Hemodialysis
    • The Hemodialysis System
    • Table 33 Hemodialysis System Market Share by Maufacturer, 2009 (%)
    • Figure 15 Hemodialysis System Market by Maufacturer, 2009 (%)
    • Acute Care Dialysis Equipment
    • Table 34 The Crrt System Market by Manuacturer, 2009
    • Table 35 Dialysis Systems and Manufacturers (HD, Pd, Crrt)
    • Dialyzers
    • Table 36 Dialyzer Products, Manufacturers, Material, and Type
    • Hemofilters
    • Table 37 Hemodialyzers, Hemofilters Market Share, 2009 (%)
    • Figure 16 Hemodialyzers, Hemofilters Market Share, 2009 (%)
    • Modes of Hemodialysis
    • Hemofiltration
    • Hemodiafiltration
    • Hemodiafiltration (Continued)
    • Figure 17 Intermittent Renal Therapies
    • Measuring Dialyzer Performance
    • Dialyzer Reuse
    • Dialysate
    • Sodium Citrate-Containing Dialysate
    • Table 38 Dialysate Products for HD, Pd, and Crrt
    • Table 38 (Continued)
    • Table 39 Dialysate Market by Manufacturer Rank, 2009
    • Dialysis Equipment Costs
    • Table 40 Costs for Common Dialysis Equipment, HD, Pd, Crrt ($)
    • The U.S. Market for Dialysis Systems and Major Consumables
    • Dialysis Machines
    • Table 41 The U.S. Market for Dialysis Systems by Type, through 2014 ($ Million)
    • Figure 18 The U.S. Market for Dialysis Systems by Type, 1996-2014 ($ Million)
    • Consumables
    • Table 42 The U.S. Market for Major Dialysis Consumables by Type, through 2014 ($ Million)
    • Figure 18 The U.S. Market for Major Dialysis Consumables by Type, 1996 - 2014 ($ Million)
    • Dialyzers
    • Dialysate
    • Peritoneal Dialysis
    • Modes of Peritoneal Dialysis
    • Continuous Ambulatory Peritoneal Dialysis
    • Figure 19 Continuous Ambulatory Peritoneal Dialysis
    • Continuous Cycler-Assisted Peritoneal Dialysis
    • Nocturnal Intermittent Peritoneal Dialysis
    • Tidal Peritoneal Dialysis
    • Dialysate for Pd
    • Peritoneal Dialysis Equipment Manufacturers
    • Table 43 Peritoneal Dialysis Systems, Type and Manufacturer
    • Table 44 Peritoneal Dialysis Equipment Market Share by Type, 2009 (%)
    • Figure 20 Peritoneal Dialysis Equipment Market by Type, 2009 (%)
    • Table 45 Peritoneal Dialysis Equipment Market Share by Manufacturer, 2009 (%)
    • Figure 21 Peritoneal Dialysis Equipment Market Share by Manufacturer, 2009 (%)
    • Continuous Renal Replacement Therapies
    • Scuf
    • Cvvh
    • Cvvhd
    • Cvvhd (Continued)
    • Figure 22 Continuous Renal Therapies (Scuf, Cvvd, Cvvhd)
    • Cvvhdf
    • Figure 23 Continuous Veno-Venous Hemodiafiltration
    • Dialysis Services
    • Table 46 Hemodialysis Treatment by Provider Type, 1990 - 2009 (%)
    • Figure 24 Hemodialysis Treatment by Provider Type, 1990 - 2009 (%)
    • Table 47 U.S. Dialysis Providers, by Type, 2008
    • Table 47 (Continued)
    • Table 47 (Continued)
    • Table 48 Market Share, Hemodialysis Providers, 2009 (%)
    • Figure 25 Market Share, Hemodialysis Providers (%)
    • The U.S. Market for Renal Replacement Therapies Used in Treating Kidney Failure
    • Hemodialysis for Treating Ckd
    • Hemodialysis for Treating Ckd (Continued)
    • Renal Replacement Therapies for Treating Arf
    • Table 49 The U.S. Market for Dialysis Therapy by Type, through 2014 ($ Million)
    • Figure 26 The U.S. Market for Dialysis Therapy by Type, 1996 to 2014 ($ Million) 116
  • Chapter-7: Renal Relacement Products and Therapies Used in Kidney Failure Treatment
  • Chapter-8: Surgical Procedures Used in Renal Failure Treatment
    • Vascular Access Procedures
    • Av Fistula
    • Figure 27 Forearm Av Fistula
    • Av Graft
    • Figure 28 A Type of Av Graft
    • Venous Catheter
    • Figure 29 Venous Catheter
    • Access Replacement/Repair
    • Vascular Access Market by Type
    • Peritoneal Dialysis Catheter
    • Figure 30 Tenckhoff Catheters
    • Pd Catheterization Costs
    • Kidney Transplantation
    • Deceased Donors
    • Living Donors
    • The Transplant Procedure
    • Donor
    • Recipient
    • Compatibility
    • Post Surgery
    • The U.S. Market for Surgical Procedures Used in Treating Renal Failure
    • The U.S. Market for Surgical ...(Continued)
    • Table 50 The U.S. Market for Surgical Procedures Used in Renal Failure Treatment by Type, through 2014 ($ Million)
    • Figure 31 The U.S. Market for Surgical Procedures Used in Renal Failure Treatment by Type, 1996-2014 ($ Million) 128
  • Chapter-9: The International Market
    • Table 54 Leading Product and Therapy Providers for Renal Failure Treatment in The U.S., 2009
    • Pharmaceuticals Manufacturers
    • Dialysis Equipment Makers
    • Manufacturers of Dialysis Consumables
    • Therapies
    • Dialysis
    • Surgery
    • Unos/Optn 140
  • Company Profiles
    • Abbott Laboratories
    • Amag Pharmaceuticals
    • American Regent Inc
    • American Renal Associates, Inc. (Ara)
    • American Vascular Dialysis Access Centers
    • Amgen
    • Asahi Kasei Kuraray Medical Co
    • Astellas Pharma U.S., Inc
    • Astrazeneca Plc
    • B.Braun Medical Inc
    • Bard Access Systems, Inc
    • Bayer Healthcare
    • Baxter International
    • Biovail Corp
    • Boehringer Ingelheim
    • Bristol Myers Squibb Company
    • Cantel Medical
    • Centers for Dialysis Care
    • Davita, Inc
    • Dialysis Clinic, Inc. (Dci)
    • Dialysis Corp. of America (Dca)
    • Diversified Specialty Institutes (Dsi)
    • Eli Lilly and Co
    • Forest Pharmaceuticals
    • Fresenius Group
    • Fresenius Group (Continued)
    • Renal Solutions, Inc
    • Gambro Ab
    • Genentech Inc
    • Genzyme Corp
    • Glaxosmithkline Plc
    • Greenfield Health Systems
    • Innovative Dialysis Systems Inc. (Ids)
    • Johnson & Johnson
    • King Pharmaceuticals
    • Kidney Center, Inc
    • Liberty Dialysis
    • Maquet Cardiovascular
    • Medcomp
    • Medigroup Inc
    • Medicines Co. (The)
    • Merck & Co
    • Mylan Bertek Pharmaceuticals
    • Navilyst Medical
    • Nipro Corp
    • Northwest Kidney Centers
    • Novartis Pharmaceuticals
    • Novo Nordisk A/S
    • Nxstage Medical
    • Par Pharmaceutical Inc
    • Pfizer
    • Prometheus Laboratories Inc
    • Regional Renal Research Institute (Rri)
    • Renal Advantage, Inc
    • Renal Ventures Management Llc
    • Roche (F. Hoffmann-La Roche Ltd.)
    • Rockwell Medical Technologies
    • Sanofi-Aventis
    • Satellite Healthcare/Wellbound
    • Shire Pharmaceuticals Group
    • Sigma-Tau Pharmaceuticals
    • Solvay Pharmaceticals, Inc
    • Takeda Pharmaceuticals
    • Terumo Corp
    • Teva Pharmaceuticals USA
    • Toray Industries, Inc
    • Transvivo
    • Ucb
    • U.S. Renal Care, Inc. (Usrc)
    • Vascular Access Centers
    • Wake Forest University Outpatient Dialysis
    • Watson Pharmaceuticals
    • Wyeth
    • Xcorporeal, Inc.
  • Appendix
+44 20 8816 8548

Ask a question about Renal Disease Treatments: Products and Therapies

Enter the characters you see in the picture below
Captcha